Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic chair resigns after failed takeover bid
14 Nov 2025, 06:43BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.

Bavarian Nordic chair resigns after failed takeover bid
13 Nov 2025, 19:48BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.

Bavarian Nordic shareholders reject private equity takeover bid
6 Nov 2025, 14:06BAVA.CONASDAQ Copenhagen

A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.

Bavarian Nordic deal struggles as vaccine contract boosts value
31 Oct 2025, 13:13BAVA.CONASDAQ Copenhagen

A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.

New EU vaccine deal complicates Bavarian Nordic takeover
31 Oct 2025, 08:21BAVA.CONASDAQ Copenhagen

Bavarian Nordic has secured a new long-term contract to supply the European Union with up to 8 million doses of its smallpox and mpox vaccine over the next four years, the company said Friday.

Private equity lowers Bavarian Nordic takeover threshold
21 Oct 2025, 12:48BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has lowered the minimum shareholder acceptance threshold for its takeover offer for Danish vaccine maker Bavarian Nordic, as it struggles to win enough support for the deal.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic receives USD 25 million milestone payment after submission of important IMVAMUNE® data to the U.S. Health Authorities19 Nov 2008
Bavarian Nordic reports successful safety data from Phase II study with IMVAMUNE®5 Nov 2008
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 September 20084 Nov 2008
Bavarian Nordic awards warrants to management and certain employees and introduces incentive programme for all employees17 Oct 2008
Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine7 Oct 2008
Bavarian Nordic A/S - Interim Report for the period 1 January to 30 June 200819 Aug 2008
Bavarian Nordic announces partnership with National Cancer Institute in the US and obtains rights to a new vaccine candidate13 Aug 2008
Bavarian Nordic files patent infringement suit against Oxford BioMedica30 Jun 2008
Bavarian Nordic reports interim data from Phase I/II studies with breast cancer vaccine19 Jun 2008
Bavarian Nordic enters clinical trials with prostate cancer vaccine3 Jun 2008
Bavarian Nordic enters clinical trials with HIV multiantigen vaccine27 May 2008
Bavarian Nordic A/S - Report on the Results of the Extraordinary General Meeting, held 26 May 200826 May 2008
  • Previous
  • 1
  • More pages
  • 58
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 59
  • 60
  • More pages
  • 78
  • Next
  • Filings
    927